查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球生物製药安全测试市场：规模/份额/趋势分析（按产品/服务/用途/测试类型）、区域前景、竞争战略、按细分市场预测（至 2030 年）
市场调查报告书
商品编码
1076144

全球生物製药安全测试市场：规模/份额/趋势分析（按产品/服务/用途/测试类型）、区域前景、竞争战略、按细分市场预测（至 2030 年）

Biologics Safety Testing Market Size, Share & Trends Analysis By Product & Service, By Application, By Test Type, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 223 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球生物製药安全检测市场预计将以 10.8% 的复合年增长率继续增长，到 2030 年将达到 85.6 亿美元。

市场的主要驱动力是大公司在生物製药和生物仿製药开发方面的大量投资、新兴市场的市场机会以及生物製药外包的增加。另一方面，缺乏熟练的专家是市场上的一个主要问题。

本报告按产品/服务分析全球生物製品安全检测市场，包括基本市场结构和主要影响因素、整体市场规模趋势展望（2019-2030）。□我们正在按应用、研究类型调查详细趋势和地区、新型冠状病毒感染 (COVID-19) 的影响以及主要公司的概况。

目录

第 1 章介绍

第 2 章调查方法

第 3 章执行摘要

第 4 章市场概述

  • 简介
  • 促进因素、抑制因素、市场机会、问题分析
  • 新型冠状病毒感染 (COVID-19)：生物安全性检测市场影响

第 5 章市场变量与展望

  • SWOT分析
  • PESTEL 分析
  • 波特五力分析
  • 热图分析

第 6 章全球生物製药安全检测市场：按产品/服务（单位：100 万美元，2019-2030）

  • 消耗品
  • 设备
  • 服务

第 7 章全球生物製药安全检测市场：按应用分类（单位：100 万美元，2019-2030）

  • 血液和血液製品的製造
  • 细胞和基因治疗产品的製造
  • 单克隆抗体製造
  • 其他用途
  • 疫苗製造

第 8 章全球生物製药安全测试市场：按测试类型（单位：100 万美元，2019-2030）

  • 生物负载测试
  • 内毒素检测
  • 支原体检测
  • 残留宿主细胞衍生蛋白/DNA检测试验
  • 无菌测试
  • 病毒安全测试

第 9 章全球生物製药安全检测市场：按地区划分（单位：100 万美元，2019-2030）

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 韩国
    • 其他亚太国家
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美国家
  • 中东/非洲
    • 沙特阿拉伯王国
    • 阿拉伯联合酋长国
    • 其他中东/非洲国家

第 10 章公司简介

  • Agilent Technologies、Inc.
    • 公司简介
    • 财务展望
    • 产品概览
    • 最新趋势
  • Almac Group
  • Associates of Cape Cod, Inc.
  • BioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • Charles River Laboratories, Inc. Lonza
  • Eurofins Scientific
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Wako Pure Chemical Corporation
  • Maravai Lifesciences
  • Merck KGaA
  • Microcoat Biotechnologie GmbH
  • Nelson Laboratories, LLC
  • Pacific BioLabs
  • PromoCell GmbH
  • QIAGEN
  • Sartorius AG
  • SGS SA
  • Thermo Fisher Scientific, Inc.
  • WuXi AppTec
简介目录
Product Code: BIOT2222

The global Biologics Safety Testing Market is projected to be worth USD 8.56 billion by 2030.

According to SPER Market Research, the Biologics Safety Testing Market is estimated to reach USD 8.56 billion by 2030 with a CAGR of 10.8%.

The expansion of the biologics and biosimilars markets, increasing concerns over cell culture contamination, and rising biopharmaceuticals research & development activities and investments, emerging markets, and growing biopharmaceutical outsourcing; are the key driver for the escalation of the market.

Impact of COVID-19 on the Biologics Safety Testing Market

To provide biologics safety testing for developing safety test kits, manufacturing of vaccines testing to treat and target the infection. Pharmaceutical and biopharmaceutical companies and the biologics safety testing market have taken steps toward research in biologics safety testing.

Scope of the report:

  • Market size available for years: 2019-2030
  • Base year considered: 2021
  • Forecast period: 2022-2030

Segments covered By Product, By Application, By End-User, By Region.

Geographies covered: North America, Europe, Asia Pacific, Latin America, Middle East, Africa.

Companies Covered:

Agilent Technologies, Inc., Almac Group, Associates of Cape Cod, Inc. BioMerieux SA, Bio-Rad Laboratories, Inc., Charles River Laboratories, Inc., Lonza, Eurofins Scientific, F. Hoffmann-La Roche Ltd., Fujifilm Wako Pure Chemical Corporation, Maravai Lifesciences, Merck KGaA, Microcoat Biotechnologie GmbH, Nelson Laboratories, LLC, Pacific BioLabs, PromoCell GmbH, Sartorius AG, SGS SA, Thermo Fisher Scientific, Inc., WuXi AppTec.

Driver: expansion in the biosimilars and biologics markets

Heavy investments in the development of biologics and biosimilars by big companies. Growth in the biosimilars and biologics markets, Growing concerns over cell culture contamination, rising biopharmaceuticals R&D activities and investments; are the key factors, which drive the market expansion.

Opportunity: Emerging markets offer profitable opportunities

Emerging markets offer rewarding opportunities, and growing biopharmaceutical outsourcing; will provide enormous opportunities in the Biologics Safety Testing Market.

Challenges: lack of skilled professionals

Lack of skilled personnel to handle the advanced technologies and the development of new and improved safety testing.

Global Biologics Safety Testing Market, By Product & Service:

Based on the Product & Service, Global Biologics Safety Testing Market is segmented as; Consumables, Instrument, and Services.

Global Biologics Safety Testing Market, By Application:

Based on the Application, Global Biologics Safety Testing Market is segmented as; Blood and Blood Products Manufacturing, Cellular & Gene Therapy Products Manufacturing, Monoclonal Antibodies Manufacturing, and Vaccine Manufacturing.

Global Biologics Safety Testing Market, By Test Type:

Based on the Test Type, Global Biologics Safety Testing Market is segmented into; Bioburden Tests, Endotoxin tests, Mycoplasma Tests, Residual Host-cell Proteins & DNA Detection Tests, Sterility tests, and Virus safety tests.

Global Biologics Safety Testing Market, By Region:

North America dominates the biggest share of the market; this is due to the increasing academic and government investments, quick expansion in the biopharmaceutical industry, growing demand for high-quality research tools for data reproducibility, and growing alertness among consumers about product safety.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the Biologics Safety Testing Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Global Biologics Safety Testing Market, By Product & Service, 2019-2030 (USD Million)

  • 6.1. Consumables
  • 6.2. Instrument
  • 6.3. Services

7. Global Biologics Safety Testing Market, By Application, 2019-2030 (USD Million)

  • 7.1. Blood and Blood Products Manufacturing
  • 7.2. Cellular & Gene Therapy Products Manufacturing
  • 7.3. Monoclonal Antibodies Manufacturing
  • 7.4. Other Application
  • 7.5. Vaccine Manufacturing

8. Global Biologics Safety Testing Market, By Test Type , 2019-2030 (USD Million)

  • 8.1. Bioburden Tests
  • 8.2. Endotoxin Test
  • 8.3. Mycoplasma Tests
  • 8.4. Residual Host-cell Proteins & DNA Detection Tests
  • 8.5. Sterility Test
  • 8.6. Virus safety Test

9. Global Biologics Safety Testing Market, By Region, 2019-2030 (USD Million)

  • 9.1. North America
    • 9.1.1. United States
    • 9.1.2. Canada
    • 9.1.3. Mexico
  • 9.2. Europe
    • 9.2.1. Germany
    • 9.2.2. United Kingdom
    • 9.2.3. France
    • 9.2.4. Italy
    • 9.2.5. Spain
    • 9.2.6. Rest of Europe
  • 9.3. Asia-Pacific
    • 9.3.1. China
    • 9.3.2. Japan
    • 9.3.3. India
    • 9.3.4. Australia
    • 9.3.5. South Korea
    • 9.3.6. Rest of Asia-Pacific
  • 9.4. South America
    • 9.4.1. Brazil
    • 9.4.2. Argentina
    • 9.4.3. Rest of South America
  • 9.5. Middle East & Africa
    • 9.5.1. Kingdom of Saudi Arabia
    • 9.5.2. United Arab Emirates
    • 9.5.3. Rest of Middle East & Africa

10. Company Profiles

  • 10.1. Agilent Technologies, Inc.
    • 10.1.1. Company details
    • 10.1.2. Financial outlook
    • 10.1.3. Product summary
    • 10.1.4. Recent developments
  • 10.2. Almac Group
    • 10.2.1. Company details
    • 10.2.2. Financial outlook
    • 10.2.3. Product summary
    • 10.2.4. Recent developments
  • 10.3. Associates of Cape Cod, Inc.
    • 10.3.1. Company details
    • 10.3.2. Financial outlook
    • 10.3.3. Product summary
    • 10.3.4. Recent developments
  • 10.4. BioMerieux SA
    • 10.4.1. Company details
    • 10.4.2. Financial outlook
    • 10.4.3. Product summary
    • 10.4.4. Recent developments
  • 10.5. Bio-Rad Laboratories, Inc.
    • 10.5.1. Company details
    • 10.5.2. Financial outlook
    • 10.5.3. Product summary
    • 10.5.4. Recent developments
  • 10.6. Charles River Laboratories, Inc. Lonza
    • 10.6.1. Company details
    • 10.6.2. Financial outlook
    • 10.6.3. Product summary
    • 10.6.4. Recent developments
  • 10.7. Eurofins Scientific
    • 10.7.1. Company details
    • 10.7.2. Financial outlook
    • 10.7.3. Product summary
    • 10.7.4. Recent developments
  • 10.8. F. Hoffmann-La Roche Ltd.
    • 10.8.1. Company details
    • 10.8.2. Financial outlook
    • 10.8.3. Product summary
    • 10.8.4. Recent developments
  • 10.9. Fujifilm Wako Pure Chemical Corporation
    • 10.9.1. Company details
    • 10.9.2. Financial outlook
    • 10.9.3. Product summary
    • 10.9.4. Recent developments
  • 10.10. Maravai Lifesciences
    • 10.10.1. Company details
    • 10.10.2. Financial outlook
    • 10.10.3. Product summary
    • 10.10.4. Recent developments
  • 10.11. Merck KGaA
    • 10.11.1. Company details
    • 10.11.2. Financial outlook
    • 10.11.3. Product summary
    • 10.11.4. Recent developments
  • 10.12. Microcoat Biotechnologie GmbH
    • 10.12.1. Company details
    • 10.12.2. Financial outlook
    • 10.12.3. Product summary
    • 10.12.4. Recent developments
  • 10.13. Nelson Laboratories, LLC
    • 10.13.1. Company details
    • 10.13.2. Financial outlook
    • 10.13.3. Product summary
    • 10.13.4. Recent developments
  • 10.14. Pacific BioLabs
    • 10.14.1. Company details
    • 10.14.2. Financial outlook
    • 10.14.3. Product summary
    • 10.14.4. Recent developments
  • 10.15. PromoCell GmbH
    • 10.15.1. Company details
    • 10.15.2. Financial outlook
    • 10.15.3. Product summary
    • 10.15.4. Recent developments
  • 10.16. QIAGEN
    • 10.16.1. Company details
    • 10.16.2. Financial outlook
    • 10.16.3. Product summary
    • 10.16.4. Recent developments
  • 10.17. Sartorius AG
    • 10.17.1. Company details
    • 10.17.2. Financial outlook
    • 10.17.3. Product summary
    • 10.17.4. Recent developments
  • 10.18. SGS SA
    • 10.18.1. Company details
    • 10.18.2. Financial outlook
    • 10.18.3. Product summary
    • 10.18.4. Recent developments
  • 10.19. Thermo Fisher Scientific, Inc.
    • 10.19.1. Company details
    • 10.19.2. Financial outlook
    • 10.19.3. Product summary
    • 10.19.4. Recent developments
  • 10.20. WuXi AppTec
    • 10.21.1. Company details
    • 10.21.2. Financial outlook
    • 10.21.3. Product summary
    • 10.21.4. Recent developments